MYnd Analytics Pitch Deck Teardown: Precision Psychiatry

Executive Summary: The Data-Driven Approach to Mental Health

MYnd Analytics presents a case for 'Precision Psychiatry.' The presentation, dated June 2019, targets investors on the NASDAQ (ticker: MYND) by framing behavioral health not just as a medical crisis, but as a data problem. The deck focuses on the inefficiency of current treatment models, where trial-and-error prescribing leads to low remission rates and high costs for payers and employers. By combining an AI-based diagnostic tool with a telepsychiatry service, MYnd attempts to offer a full-stack solution for primary care providers who are often the first line of defense in mental health but lack specialized tools.

Slide 1: Title and Positioning

The cover slide establishes MYnd Analytics as a behavioral health company focused on tools and technology. The subtitle explicitly states the value proposition: improving access to care and reducing trial-and-error prescribing to improve outcomes and lower costs. The inclusion of the NASDAQ ticker immediately signals that this is a public company presentation, likely intended for institutional investors or retail shareholders following a specific earnings period or corporate milestone.

Slide 4: The Behavioral Health Crisis

This slide uses a funnel graphic to illustrate the massive drop-off in effective mental health treatment. It notes that while 90 million people in the U.S. suffer from depression, only 27% receive treatment, and a staggering 2.7% of the total depressed population achieves remission. The slide cites a $31B loss in annual productivity and a projected $4.31B market size for mental health software by 2025. This sets the 'Problem' stage by highlighting both the human cost and the commercial opportunity.

Slide 7: The ABC’s of Behavioral Health

MYnd breaks its solution into three categories: Access, Better Care, and Costs. Access is solved via Arcadian Telepsychiatry’s national network. Better Care is addressed through PEER Online, which the slide claims has a 'greater than 80% probability' of identifying the right medication at first treatment, based on internal data (0.81 sensitivity/0.85 specificity). Costs are reduced by eliminating the visits and prescriptions associated with failed trial-and-error cycles. The slide effectively maps these solutions to three distinct stakeholders: Patients, Health Systems, and Payers.

Slide 10: PEER Online Workflow

This slide explains the technical process of the PEER Online tool. It follows a six-step linear path: 1. EEG scan at a primary care office; 2. Secure upload to PEER Online; 3. Comparison against 40,000 data points; 4. Generation of an AI-driven report; 5. Consultation with a MYnd psychiatrist; 6. Creation of a personalized treatment plan. This visualization is crucial for investors to understand how a complex AI/biotech product actually integrates into a standard doctor's visit.

Slide 13: Clinical Validation and Testimonials

Rather than showing raw data tables, Slide 13 uses 'What Doctors Say' to build credibility. It features quotes from high-profile figures, including the Chief of Clinical Pathology at Quest Diagnostics and a professor from Stanford University School of Medicine. The quotes emphasize the need for objective measures in psychiatry, comparing the brain to other organs that are routinely measured before treatment. This slide serves as a powerful form of social proof for a technology that might otherwise seem experimental to conservative investors.

Slide 16: The Integrated Service Model

This slide illustrates the 'Differentiated Behavioral Health Technology and Services' model. It shows how a patient moves from identification in a primary care clinic to either a PEER-informed treatment plan, telepsychiatry for complex cases, or flexible tele-therapy. By showing these three paths, MYnd demonstrates that it isn't just a software company; it is a service provider capable of handling varying levels of patient acuity.

Slide 19: Recent Developments and Scalability

Slide 19 lists five key milestones intended to show momentum. These include partnerships with Sanford Health and Memorial Hospital Gulfport, and a nationwide expansion for a 'leading EAP provider.' The most significant technical milestone listed is the FDA designated breakthrough device status for PEER Online. This is a critical value inflection point for healthcare investors, as it suggests a cleared regulatory path and recognized clinical novelty.

Slide 22: Summary of Value

The summary reiterates the core themes: personalized therapy, greater access, and lower costs. It positions the company as being 'well positioned' to help a wide array of stakeholders, including government and employers. The language here is broad, designed to leave the investor with a sense of the company’s wide-reaching potential across the entire healthcare ecosystem.

Slide 25: Contact and Leadership

The final slide provides contact information for three key executives: Robin L. Smith (Chairman), Patrick Herguth (CEO), and Don D’Ambrosio (CFO). While the deck lacks a traditional 'Team' slide with biographies and past successes, this contact page at least identifies the top-tier management responsible for the company’s strategy.

What MYnd Analytics Does Well

The deck excels at defining a clear, quantifiable problem. By citing the 2.7% remission rate, they make the current standard of care look objectively broken. The use of a simple 'ABC' framework (Access, Better Care, Costs) makes a complex med-tech play easy to digest for generalist investors. Furthermore, the workflow diagram on Slide 10 demystifies the technology, showing that the barrier to entry for a primary care physician is just an EEG scan and an upload.

What is Missing from the Deck

For a public company presentation, there is a surprising lack of hard financial data. There are no slides showing quarterly revenue growth, gross margins for the telepsychiatry business versus the software business, or a balance sheet summary. Additionally, the deck does not address the competitive landscape. While they mention their solution is 'differentiated,' they do not name other telepsychiatry providers or digital health companies like Ginger or Teladoc, which were active in the space in 2019. Finally, the absence of a detailed team slide is a missed opportunity to highlight the clinical and operational pedigree of the leadership team beyond their names and phone numbers.

Founder Takeaways: Lessons from MYnd

Quantify the Failure of the Status Quo: If your product improves an existing process, don't just say it's 'better.' Use statistics to show how poorly the current system performs, as MYnd did with remission rates on Slide 4. · Map Benefits to Every Stakeholder: In healthcare, the person using the tool (doctor), the person benefiting (patient), and the person paying (payer) are often different. Slide 7 is a great example of how to address all three in one view. · Use Workflow Diagrams: For AI or complex backend technologies, show the 'User Journey.' Slide 10 takes the 'black box' of AI and turns it into a familiar six-step clinical process. · Leverage Regulatory Wins: If you have FDA breakthrough status or similar designations, make it a headline. It is one of the strongest de-risking signals you can send to a healthcare investor.